- Home
- LXRX vs SGP Comparison
LXRX vs SGP Comparison
Compare LXRX & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | SGP |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | United States |
| Employees | 81 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 891.1M |
| IPO Year | 2000 | 2026 |
Fundamental Metrics
Financial Performance| Metric | LXRX | SGP |
|---|---|---|
| Price | $2.29 | $26.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.15 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 2.7M | 60.9K |
| Earning Date | 05-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $1.03 | $17.06 |
| 52 Week High | $2.68 | $30.56 |
Technical Indicators
Market Signals| Indicator | LXRX | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 63.77 |
| Support Level | $2.17 | $24.87 |
| Resistance Level | $2.49 | $27.53 |
| Average True Range (ATR) | 0.10 | 1.14 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 34.43 | 62.37 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.